Efgartigimod alfa
Contents
Description
Efgartigimod alfa is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), reducing pathogenic IgG antibodies. It is approved for generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody positive. The drug offers a novel mechanism targeting the underlying autoantibody pathology with intravenous infusion cycles.
Indications & Therapeutic Use
Generalized myasthenia gravis (gMG) in AChR antibody-positive adults
Linked Diseases:
Global Availability (6 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Efgartigimod alfa — GNH India
21 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Browse all Efgartigimod alfa products on GNH IndiaProducts and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
| Generic Name | efgartigimod alfa |
| Brands | 1 brand available |
| Active Ingredient | efgartigimod alfa-fcab |
| Drug Class | Generalized myasthenia gravis (gMG) in AChR antibody-positive adults |
| Manufacturer | argenx |
| Dosage Forms | Intravenous infusion, 400mg/20mL solution |
| Medical Code | L04AA52 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved (2021), EMA Approved (2022), Japan Approved (2022) |
| Clinical Trial | NCT03669588 |
| Countries | 6 countries |